STAR指南针:基于欧盟药物警戒体系十年回顾的未来方向
本文回顾了2010年欧盟药物警戒立法,认为通过制药公司和监管机构的新职责以及EU-GVP实践,患者和公共卫生保护目标已实现;并提出STAR原则(与卫生系统协同互动、可信证据、自适应流程效率、应急准备)以指导未来药物警戒发展。
要点
- 欧盟2010年药物警戒立法目标已实现,并由EU-GVP良好实践支持。
- 未来药物警戒需遵循STAR原则:协同、可信证据、效率、应急准备。
- STAR原则应指导能力建设、技术方法、监管流程及政策研究。
核心结论
- 欧盟2010年药物警戒立法的患者和公共卫生保护目标被认为已实现,并得到EU-GVP良好实践的支持。
研究设计与样本
- 本文为对欧盟药物警戒体系十年回顾的反思性文章,未报告系统检索或样本量。
主要发现
- 通过赋予制药公司和监管机构新职责,立法目标已实现。
- 提出STAR原则以指导未来药物警戒系统的发展。
关键数值与推荐
- STAR原则包括:与卫生系统协同互动、可信证据用于监管决策、自适应流程效率、应急准备。
临床怎么用
- 临床药学智能体可参考STAR原则,在药物警戒中注重与卫生系统协同、证据可信度、流程效率和应急准备。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article reflects on the 2010 pharmacovigilance legislation of the European Union (EU). Its legislative aim of better patient and public health protection through new responsibilities for pharmaceutical companies and regulatory bodies is considered to have been achieved and is well supported by the good pharmacovigilance practices 'EU-GVP'. For future progress, we set out a vision for high-quality pharmacovigilance in a world of ongoing medical, technological and social changes. To deliver this vision, four principles are proposed to guide actions for further progressing the EU pharmacovigilance system: synergistic interactions with healthcare systems; trustworthy evidence for regulatory decisions; adaptive process efficiency; and readiness for emergency situations (the 'STAR principles'). Like a compass, these principles should guide actions for building capacity, technology and methods; improving regulatory processes; and expanding policies, frameworks and research agendas. Fit for the future, the EU system should achieve further improved outputs in terms of safe, effective and trusted use of medicines and positive health outcomes within patient-centred healthcare.
引用
- Bahri P, Genov G, Arlett P, et al. The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System. Drug Saf. 2024. PMID: 38987419. doi:10.1007/s40264-024-01451-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。